Consensus statement: Guidelines for PSA following radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 37, Issue 5, 1997, Pages 1035-1041

  Cox, James D ^a   Grignon, David J ^b   Kaplan, Richard S ^c   Parsons, James T ^d   Schellhammer, Paul F ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; HUMAN; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; SOCIETIES, MEDICAL; TREATMENT FAILURE;

EID: 0030906817     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00002-3     Document Type: Article

References (10)

1. Anderson, J. R.; Cain, K. C.; Gelber, R. D. Analysis of survival by tumor response. J. Clin. Oncol. 1:710-719; 1983.
2. Breiman, L.; Friedman, J. H.; Olshen, R. A.; Stone, C. J. Classification and regression trees. New York: International Thomson Publishing/Chapman and Hall; 1984.
3. Cox, R. S.; Kaplan, I. D.; Bagshaw, M. A. Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 28:23-31; 1994.
4. Kuban, D. A.; El-Mahdi, A. M.; Schellhammer, P. F. Prostate-specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:307-315; 1995.
5. Pinover, W. H.; Hanlon, A. L.; Movsas, B.; Hanks, G. E. The correlation of PSA nadir and biochemical freedom from cancer after external beam treatment: effects of stage, grade, and pretreatment PSA groupings (in press).
6. Sartor, C.; Strawderman, M.; Lin, X.; Kish, K.; McLaughlin, P.; Sandler, H. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (in press).
7. Willett, C. G.; Zietman, A. L.; Shipley, W. U.; Coen, J. J. The effect of pelvic radiation therapy on the production of prostatic-specific antigen. J. Urol. 151:1579-1581; 1994.
8. Zagars, G. K.; Pollack, A.; Kavadi, V.; von Eschenbach, A. C. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:293-306; 1995.
9. Zietman, A. L.; Coen, B. S.; Dallaw, K. C.; Shipley, W. U. The treatment of prostate cancer by conventional radiotherapy: an analysis of long-term outcome. Int. J. Radiat. Oncol. Biol. Phys. 32:287-292; 1995.
10. Zietman, A. L.; Tibbs, M. K.; Dallow, K. C.; Althausen, A. F.; Willett, C. G.; McGovern, F. G.; Shipley, W. U. The use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother. Oncol. 40:159-162; 1996.